Skip to main navigation
  • Recent News
  • Investors
  • Contact Us
Avadel pharmaceutical logo
  • Home
  • Our Focus
  • Culture & Careers
  • Recent News
  • Investors
  • Contact Us

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases
  4. Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Press Releases

Printer Friendly Version View printer-friendly version << Back
February 3, 2023 at 8:00 AM EST

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PDF Version

DUBLIN, Ireland, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new employees to purchase an aggregate of 38,000 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employees’ acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the grant date and 25% on each anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688


Primary Logo

Source: Avadel Pharmaceuticals plc

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts
  • Our Focus
  • Culture & Careers
  • Investors
  • Recent News
  • Contact Us
  • Home
  • Our Focus
  • Culture & Careers
  • Contact Us
  • Recent News
  • Investors
  • Privacy Policy
  • Corporate Compliance
  • Terms and Conditions

The Avadel logo, the droplet brand mark, and other brands are trademarks of an Avadel company. © 2022 Avadel. All rights reserved.

PM-US-AVGEN-0115

We Care About Your Privacy

This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our updated Privacy Policy.

You are about to leave the Avadel website.

Do you want to continue?

Avadel is not responsible for the content or availability of third party sites.